Niels van de Donk

PROF.DR., (Principal Investigator)


Research output per year

If you made any changes in Pure these will be visible here soon.

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS)

Landgren, C. O., Chari, A., Cohen, Y. C., Spencer, A., Voorhees, P., Estell, J. A., Sandhu, I., Jenner, M. W., Williams, C., Cavo, M., van de Donk, N. W. C. J., Beksac, M., Moreau, P., Goldschmidt, H., Kuppens, S., Bandekar, R., Clemens, P. L., Neff, T., Heuck, C., Qi, M. & 1 others, Hofmeister, C. C., 1 Jan 2020, In : Leukemia. 34, 7, 13 p.

Research output: Contribution to journalArticleAcademicpeer-review

Open Access

Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials

Usmani, S. Z., Nahi, H., Plesner, T., Weiss, B. M., Bahlis, N. J., Belch, A., Voorhees, P. M., Laubach, J. P., van de Donk, N. W. C. J., Ahmadi, T., Uhlar, C. M., Wang, J., Feng, H., Qi, M., Richardson, P. G. & Lonial, S., Jun 2020, In : The Lancet Haematology. 7, 6, p. e447-e455

Research output: Contribution to journalArticleAcademicpeer-review

Preclinical Activity of JNJ-7957, a Novel BCMA×CD3 Bispecific Antibody for the Treatment of Multiple Myeloma, Is Potentiated by Daratumumab

Frerichs, K. A., Broekmans, M. E. C., Marin Soto, J. A., van Kessel, B., Heymans, M. W., Holthof, L. C., Verkleij, C. P. M., Boominathan, R., Vaidya, B., Sendecki, J., Axel, A., Gaudet, F., Pillarisetti, K., Zweegman, S., Adams, H. C., Mutis, T. & van de Donk, N. W. C. J., 1 May 2020, In : Clinical cancer research : an official journal of the American Association for Cancer Research. 26, 9, p. 2203-2215 13 p.

Research output: Contribution to journalArticleAcademicpeer-review

Open Access

Preclinical evidence for an effective therapeutic activity of FL118, a novel survivin inhibitor, in patients with relapsed/refractory multiple myeloma

Holthof, L. C., van der Horst, H. J., van Hal-van Veen, S. E., Ruiter, R. W. J., Li, F., Buijze, M., Andersen, M. N., Yuan, H., de Bruijn, J., van de Donk, N. W. C. J., Lokhorst, H. M., Zweegman, S., Groen, R. W. J. & Mutis, T., 1 Jan 2020, In : Haematologica. 105, 2, p. e80-e83

Research output: Contribution to journalLetterAcademicpeer-review

Open Access

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

Moreau, P., Attal, M., Hulin, C., Arnulf, B., Belhadj, K., Benboubker, L., Béné, M. C., Broijl, A., Caillon, H. L., Caillot, D., Corre, J., Delforge, M., Dejoie, T., Doyen, C., Facon, T., Sonntag, C. C., Fontan, J., Garderet, L., Jie, K-S., Karlin, L. & 38 others, Kuhnowski, F., Lambert, J. R., Leleu, X., Lenain, P., Macro, M., Mathiot, C., Orsini-Piocelle, F., Perrot, A., Stoppa, A-M., van de Donk, N. W. CJ., Wuilleme, S., Zweegman, S., Kolb, B., Touzeau, C., Roussel, M., Tiab, M., Marolleau, J-P., Meuleman, N., Vekemans, M-C., Westerman, M., Klein, S. K., Levin, M-D., Fermand, J. P., Escoffre-Barbe, M., Eveillard, J-R., Garidi, R., Ahmadi, T., Zhuang, S., Chiu, C., Pei, L., de Boer, C., Smith, E., Deraedt, W., Kampfenkel, T., Schecter, J., Vermeulen, J., Avet-Loiseau, H. & Sonneveld, P., 6 Jul 2019, In : The Lancet. 394, 10192, p. 29-38

Research output: Contribution to journalArticleAcademicpeer-review